Heerspink, Hiddo
Nolan, Stephen
Carrero, Juan-Jesus
Arnold, Matthew
Pecoits-Filho, Roberto
García Sánchez, Juan José
Wittbrodt, Eric
Cabrera, Claudia
Lam, Carolyn S. P.
Chen, Hungta
Kanda, Eiichiro
Lainscak, Mitja
Pollock, Carol
Wheeler, David C.
Funding for this research was provided by:
AstraZeneca
Article History
Received: 14 March 2024
Accepted: 24 May 2024
First Online: 3 July 2024
Declarations
:
: Hiddo Heerspink reports grants and other fees from AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Pharma, Dimerix, Gilead, Janssen, Merck, Mitsubishi Tanabe, Mundipharma, Novo Nordisk, and Retrophin. Stephen Nolan, Matthew Arnold, Juan José García Sánchez, Eric Wittbrodt, Claudia Cabrera, and Hungta Chen are employees of, and may hold stock and/or stock options in, AstraZeneca. Juan-Jesus Carrero reports institutional grants from Astellas, AstraZeneca, and Vifor Pharma; speaker fees from AstraZeneca, Abbott, and Nutricia; and consultancy for AstraZeneca and Bayer. Roberto Pecoits-Filho is an employee of Arbor Research Collaborative for Health, which receives global support for the ongoing Dialysis Outcomes and Practice Patterns Study Programs (provided without restriction on publications by a variety of funders; for details see ). Roberto Pecoits-Filho also reports research grants from Fresenius Medical Care, non-financial support from Akebia, AstraZeneca, Bayer, Boehringer, Novo Nordisk, and FibroGen; as well as personal fees from Travere Therapeutics and consulting fees from George Clinical outside the submitted work. Carolyn S.P. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, Medtronic, Roche Diagnostics, and Vifor Pharma; has served as a consultant or on the advisory board/steering committee/executive committee for Abbott Diagnostics, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Biofourmis, Boehringer Ingelheim, Boston Scientific, Corvia Medical, Cytokinetics, Darma Inc., Eko.ai Pte Ltd, Jana Care, Janssen Research & Development LLC, Medtronic, Menarini Group, Merck, MyoKardia, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics, Sanofi, Stealth BioTherapeutics, The Corpus, Vifor Pharma, and WebMD Global LLC; and serves as co-founder and non-executive director of Us2.ai Pte Ltd. Eiichiro Kanda is a consultant for AstraZeneca. Mitja Lainscak is supported by the Slovenian Research Agency; has received research support from Roche Diagnostics; has served as a consultant or on the advisory board/steering committee for AstraZeneca, Boehringer Ingelheim, Novartis, and Vifor Pharma; has received personal fees from Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Novartis, Sanofi, Servier, and Vifor Pharma. Carol Pollock reports advisory board membership for AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Vifor Pharma; as well as speaker fees for AstraZeneca, Janssen-Cilag, Novartis, Otsuka, and Vifor Pharma. David C. Wheeler reports personal fees and non-financial support from AstraZeneca, as well as personal fees from Astellas, Bayer, Boehringer Ingelheim, GSK, Janssen, Mundipharma, Napp, Reata Pharmaceuticals, Tricida, and Vifor Fresenius.
: This study was performed in accordance with ethical principles consistent with the Declaration of Helsinki, International Conference on Harmonisation, Good Clinical Practice, and the applicable legislation on noninterventional studies and observational studies. This study used de-identified data and did not require data collection beyond that of routine clinical care. No identifiable information was collected or examined as part of the study. Ethical and scientific approval for use of CPRD data in the current study was obtained from the Independent Scientific Advisory Committee of CPRD (protocol number 19_172). Informed consent was waived by the East Midlands – Derby Research Ethics Committee because CPRD data are anonymized for research purposes (for further information, see ). Ethics approval was not required for use of data from the US TriNetX and Japan Medical Data Vision for this study, in accordance with local or national guidelines.